Tiziana Life Sciences Ltd (TLSA)

Market Cap	186.33M +11.4%
Revenue (ttm)	n/a
Net Income	-18.43M
EPS	-0.16
Shares Out	127.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,145,911
Open	1.610
Previous Close	1.610
Day's Range	1.460 - 1.850
52-Week Range	1.140 - 2.600
Beta	0.40
Analysts	Strong Buy
Price Target	5.93 (+306.16%)
Earnings Date	May 1, 2026

About TLSA

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 24, 2000
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSA
• Website: https://www.tizianalifesciences.com

Analyst Summary

According to one analyst, the rating for TLSA stock is "Strong Buy" and the 12-month stock price target is $5.93.

Price Target

$5.93

(306.16% upside)

Analyst Consensus: Strong Buy